Plasma treatment for healing chronic wounds


Tuesday, 20 February, 2024

Plasma treatment for healing chronic wounds

More than 420,000 Australians are estimated to suffer from a chronic wound each year, costing the health and aged care system a total of $3bn.

Globally, over 540 million people worldwide are living with diabetes, of which 30% develop a foot ulcer during their lifetime. The cost of managing chronic wounds such as diabetic foot ulcers already exceeds $US17 billion annually, and with rise in obesity cases and lack of exercise, this number is expected to increase in coming decades, according to the University of South Australia (UniSA).

Now, a team of international scientists, led by UniSA physicist Dr Endre Szili, has developed new treatment for chronic wounds that does not involve antibiotics or silver-based dressings, but an ionised gas called plasma. It involves boosting the plasma activation of hydrogel dressings with a unique mix of different chemical oxidants that decontaminate and help heal chronic wounds.

The study, published in Advanced Functional Materials, describes the new method as “a significant breakthrough” that could revolutionise the treatment of diabetic foot ulcers, internal wounds and potentially cancerous tumours.

“Antibiotics and silver dressings are commonly used to treat chronic wounds, but both have drawbacks. Growing resistance to antibiotics is a global challenge and there are also major concerns over silver-induced toxicity. In Europe, silver dressings are being phased out for this reason,” Szili said.

The benefits of cold plasma ionised gas have already been proven in clinical trials, showing it controls not only infection but also stimulates healing — this is due to the potent chemical cocktail of oxidants, namely reactive oxygen and nitrogen species (RONS) it produces when it mixes and activates the oxygen and nitrogen molecules in the ambient air, the researchers suggested.

Szili and his colleagues have shown that plasma activating hydrogel dressings with RONS makes the gel far more powerful, killing common bacteria. Although diabetic foot ulcers were the focus of this study, the technology could be applied to all chronic wounds and internal infections.


 

“Despite recent encouraging results in the use of plasma activated hydrogel therapy (PAHT), we faced the challenge of loading hydrogels with sufficient concentrations of RONS required for clinical use. We have overcome this hurdle by employing a new electrochemical method that enhances the hydrogel activation,” Szili said.

As well as killing common bacteria (E. coli and P. aeruginosa) that cause wounds to become infected, the researchers said that the plasma activated hydrogels might also help trigger the body’s immune system, which can help fight infections.

“Chronic wound infections are a silent pandemic threatening to become a global healthcare crisis. It is imperative that we find alternative treatments to antibiotics and silver dressings because when these treatments don’t work, amputations often occur,” Szili said.

“A major advantage of our PAHT technology is that it can be used for treating all wounds. It is an environmentally safe treatment that uses the natural components in air and water to make its active ingredients, which degrade to non-toxic and biocompatible components.”

Szili said that in future, plasma could be used to treat cancerous tumours by activating drugs contained within gels injected into the body.

“The active ingredients could be delivered over a lengthy period, improving treatment, with a better chance of penetrating a tumour. Plasma has massive potential in the medical world, and this is just the tip of the iceberg.”

The next step will involve clinical trials to optimise the electrochemical technology for treatment in human patients, Szili said.

Image credit: iStock.com/travenian

Related News

Non-invasive 'virtual' biopsy for skin cancer diagnosis

Researchers have developed a new imaging method that allows clinicians to analyse the skin...

UTI vaccines could prevent infection for nine years

MV140 is a new vaccine for recurrent UTIs and is administered with two sprays of a...

What's the key to retaining rural GPs?

Understanding doctors' decisions to stay or leave, once recruited, could provide insights on...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd